Medicus Pharma reported Q2 2026 financial results highlighting progress in its SkinJect and Teverelix drug programs, including FDA and UAE approvals for key studies. The company raised about $40 million through equity and debt in H1 2026, improving its cash position to $25.2 million. Despite increased operating expenses and a net loss of $11.7 million, Medicus is advancing toward late-stage development with plans for further clinical milestones and strategic partnerships. The company also noted the need for additional financing to sustain operations.
Nvidia reported record revenue growth of 105.85% year-over-year in Q2 FY2027 and projects 70% growth for FY2028 despite supply constraints. The company is accelerating its capital return program, having returned 60% of free cash flow year-to-date thr...
American Airlines has rejected a merger proposal from United Airlines, leaving it to face a challenging turnaround amid a weak balance sheet and tough competition. While Delta and United have seen significant stock gains over the past decade, America...
Nvidia Corporation reported a record revenue of $96.2 billion for Q2 FY27, marking a 106% increase year-over-year, driven by strong demand for AI infrastructure. The company raised its preliminary growth outlook for FY28 to about 70%, citing continue...
Nvidia has reportedly agreed to acquire Hugging Face, a leading platform for hosting open-weight AI models, for approximately $13 billion. This deal marks one of Nvidia's largest acquisitions and follows recent discussions about the importance of ope...
Leifras Co., Ltd. secured a new contract in April 2026 to manage weekend community club activities at 19 public junior high schools in Chiba City, Japan. This marks Leifras' first contract in Chiba and aligns with Japan's national policy to shift sch...
